1. Home
  2. SNGX vs MTEX Comparison

SNGX vs MTEX Comparison

Compare SNGX & MTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • MTEX
  • Stock Information
  • Founded
  • SNGX 1987
  • MTEX 1993
  • Country
  • SNGX United States
  • MTEX United States
  • Employees
  • SNGX N/A
  • MTEX N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • MTEX Medicinal Chemicals and Botanical Products
  • Sector
  • SNGX Health Care
  • MTEX Health Care
  • Exchange
  • SNGX Nasdaq
  • MTEX Nasdaq
  • Market Cap
  • SNGX 13.8M
  • MTEX 15.8M
  • IPO Year
  • SNGX 1987
  • MTEX 1999
  • Fundamental
  • Price
  • SNGX $1.34
  • MTEX $9.00
  • Analyst Decision
  • SNGX Strong Buy
  • MTEX
  • Analyst Count
  • SNGX 1
  • MTEX 0
  • Target Price
  • SNGX $6.00
  • MTEX N/A
  • AVG Volume (30 Days)
  • SNGX 697.0K
  • MTEX 64.5K
  • Earning Date
  • SNGX 11-10-2025
  • MTEX 11-07-2025
  • Dividend Yield
  • SNGX N/A
  • MTEX N/A
  • EPS Growth
  • SNGX N/A
  • MTEX N/A
  • EPS
  • SNGX N/A
  • MTEX N/A
  • Revenue
  • SNGX N/A
  • MTEX $112,975,000.00
  • Revenue This Year
  • SNGX N/A
  • MTEX N/A
  • Revenue Next Year
  • SNGX N/A
  • MTEX N/A
  • P/E Ratio
  • SNGX N/A
  • MTEX N/A
  • Revenue Growth
  • SNGX N/A
  • MTEX N/A
  • 52 Week Low
  • SNGX $1.09
  • MTEX $7.46
  • 52 Week High
  • SNGX $6.23
  • MTEX $16.49
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 34.06
  • MTEX 49.29
  • Support Level
  • SNGX $1.54
  • MTEX $8.64
  • Resistance Level
  • SNGX $1.61
  • MTEX $12.45
  • Average True Range (ATR)
  • SNGX 0.10
  • MTEX 0.75
  • MACD
  • SNGX 0.01
  • MTEX 0.01
  • Stochastic Oscillator
  • SNGX 8.70
  • MTEX 12.84

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About MTEX Mannatech Incorporated

Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.

Share on Social Networks: